Our Resources | Association for Accessible Medicines

In the News - AAM CEO Dan Leonard shares the industry's 2021 outlook with Chain Drug Review.

Nitrosamines: An Industry Position Paper Based on Risk

Oct 6, 2020 | Erica Klinger

White Paper: Nitrosamines — An Industry Position Paper Based on Risk

2020 Generic Drug and Biosimilars Access & Savings in the U.S. Report - Cover image

Sep 29, 2020 | Erica Klinger

2020 Generic Drug & Biosimilars Access and Savings in the U.S. Report

AAM Blueprint Supply Chain Header

Apr 30, 2020 | Erica Klinger

A Blueprint for Enhancing the Security of the U.S. Pharmaceutical Supply Chain

Feb 20, 2020 | Craig Burton

White Paper: Medicare and Commercial Plans Fail to Get New Generics to Patients

Jan 23, 2020 | Craig Burton

White Paper: Sidelined: How Seniors Miss Out On Savings Available Through Generic Substitution

Sep 20, 2019 | Craig Burton

White Paper: Access Denied: Why New Generics Are Not Reaching America's Seniors

Sep 18, 2019 | Erica Klinger

Report: 2019 Generic Drug & Biosimilars Access & Savings in the U.S.

White Paper: Biosimilars Council Failure to Launch Part 2

Sep 9, 2019 | Craig Burton

White Paper Part 2: Failure to Launch: Barriers to Biosimilar Market Adoption

Jun 25, 2019 | Christine Simmon

White Paper (Part 1) Failure to Launch: Patent Abuse Blocks Access to Biosimilars for America's Patients

Quality Generic Drug Manufacturing

Apr 27, 2019 | Allen Goldberg

Commitment to Quality Excellence

Fix the USMCA trade agreement

Apr 24, 2019 | Erica Klinger

The USMCA Will Keep Drug Prices Out of Reach for Patients, But Congress Can Fix It

Apr 11, 2019 | Erica Klinger

AAM Code of Business Ethics